Axcella Health Inc. Stock News

Axcella Health (NASDAQ: AXLA ) stock is on the rise Wednesday as investors react to an update from the FDA. That update has to do with the company's Long Covid  Fatigue treatment currently in develop

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous

Penny stocks with news that has turned heads in the stock market this week. The post Penny Stocks To Buy Now?

Penny stocks to watch after big news this week. The post 4 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Axcella Health (NASDAQ: AXLA ) stock is rocketing higher on Tuesday after revealing a regulatory path to registration for AXA1125. Investors will note that AXA1125 is the company's treatment for Long

Use these tools to find cheap penny stocks to buy The post How to Find Undervalued Penny Stocks: Quick Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Axcella Health Inc. (AXLA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings

CAMBRIDGE, Mass.

Axcella Health Inc. (NASDAQ:AXLA ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Bill Hinshaw - President & CEO Bob Crane - CFO Margaret Koziel - CMO Conference Cal

Shares of Axcella Therapeutics Inc. AXLA, +6.79% gained 10.9% in premarket trading on Thursday after the biotech said its experimental treatment for nonalcoholic steatohepatitis (NASH) showed statisti

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 stu

Zosano (ZSAN) is set to provide updates on the development path ahead for its lead candidate, M207, when it reports earnings results for first-quarter 2022.

The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly

TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.